The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | The comprehensive HHT outcomes registry of the United States (CHORUS)
Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, shares Data from the comprehensive hereditary hemorrhagic telangiectasia (HHT) outcomes registry of the United States (CHORUS). Dr Al-Samkari highlights the key findings from the report, including the high prevalence of moderate to severe mucosal bleeding, heavy menstrual bleeding, and serious neurologic and cardiopulmonary complications. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
